This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents:
Piperacillin/tazobactam; ticarcillin-clavulanate
Indication:
Treatment of adults with complicated intra-abdominal infections and complicated urinary tract infections
Mechanism of action:
Inhibition of cell wall synthesis (cephalosporin) and beta-lactamase inhibitor
Common adverse effects:
Nausea, diarrhea, headache, pyrexia
Dosage form & strength:
Injection; ceftolozane 1 g/tazobactam 0.5 mg per vial
Product labeling:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf
Diclofenac sodium -Dyloject (Javelin Pharms)
Comparative agents: Ketorolac
Indication:
Use in adults for the management of mild to moderate pain and management of moderate to severe pain alone or in combination with opioid analgesics.
Mechanism of action:
Inhibition of the cyclooxygenase (COX-1 and COX-2) pathways and inhibition of prostaglandin synthetase ) with at least one weight-related comorbidity such as type 2 diabetes and cardiovascular disease
Glucagon-like peptide-1 analogue 
Nivolumab -Opdivo (Bristol-Myers Squibb)
Comparative agents: None
Indication:
Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor
Mechanism of action:
Human programmed death receptor-1 (PD-1) blocking antibody
Common adverse effects: Rash

Dosage form & strength:
Injection; 400 mg/4 mL, 100 mg/10 mL vials 
